---

The Editorial Board

• A Akbar, University College London, United Kingdom
• P Askenase, Yale Medical School, United States
• M Bonneville, Inserm, France
• C G Brooks, University of Newcastle, United Kingdom
• R Coffman, DynaVax Technologies, United States
• D M Davis, Imperial College, United Kingdom
• S Davis, University of Oxford, United Kingdom
• J Davoust, Inserm, France
• T Defrance, Institut National de la Sante, France
• M Dustin, Howard Hughes Medical Institute, United States
• T Evans, University of Glasgow, United Kingdom
• P Garside, University of Strathcylde, United Kingdom
• D Gray, University of Edinburgh, United Kingdom
• A Hayday, Kings College London, United Kingdom
• S Hedrick, University of California, San Diego, United States
• H Hensgartner, University Hospital of Zurich, Switzerland
• T Hussell, Imperial College, United Kingdom
• S Koyasu, Keio University, Japan
• G Macpherson, University of Oxford, United Kingdom
• F Marelli-Berg, Imperial College, London
• A van der Merwe, Sir William Dunn School of Pathology, United Kingdom
• A O'Garra, National Institute Medical Research, United Kingdom
• F Powrie, Sir William Dunn School of Pathology, United Kingdom
• C Reis e Sousa, London Research Institute, United Kingdom
• C Rudd, Imperial College, United Kingdom
• D M Sansom, University of Birmingham, United Kingdom
• K C Smith, Cambridge Institute for Medical Research, United Kingdom
• R M Steinman, The Rockfeller University, United States
• B Stockinger, National Institute for Medical Research, United Kingdom
• S Todryk, University of Oxford, United Kingdom
• F Wang, Research Center for Biological Therapy, Beijing
• S Ward, Bath University, United Kingdom
• S F Wong, University of Bristol, United Kingdom
• JM Woof, University of Dundee, United Kingdom
• D Xu, University of Glasgow, United Kingdom